UK biotech firm Circassia Pharmaceuticals (LSE: CIR) has completed its agreement with AstraZeneca (LSE: AZN) to buy certain US commercial rights to two chronic obstructive pulmonary disease products.
Shares in Circassia leapt almost a quarter when the company announced the transaction in mid-March.
The products, Tudorza (aclidinium) and Duaklir (formoterol fumarate dihydrate/aclidinium bromide) were purchased for a maximum total consideration of $230 million, plus sales-based royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze